A5071013248- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Biosimilars and Bioanalytical Methods
- Polyomavirus and related diseases
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Renal Transplantation Outcomes and Treatments
- SARS-CoV-2 and COVID-19 Research
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Integrated Circuits and Semiconductor Failure Analysis
- Cancer Immunotherapy and Biomarkers
- Cytomegalovirus and herpesvirus research
- Biomedical Ethics and Regulation
- Blood groups and transfusion
- Viral-associated cancers and disorders
University of Maryland, Baltimore
2016-2025
University of Maryland Medical Center
2023-2025
U-M Rogel Cancer Center
2015-2024
National Institutes of Health
2008-2024
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2015-2023
University of Maryland Medical System
2021
University of Maryland, College Park
2020
National Cancer Institute
2005-2015
Center for Cancer Research
2005-2015
National Cancer Institute
2013
Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched donor, with significant disparity across ethnic groups. We hypothesized that HCT a mismatched (MMUD) post-transplant cyclophosphamide (PTCy), novel strategy successful in overcoming genetic related donors, would be feasible and...
In the Second Annual National Cancer Institute's Workshop on Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, Scientific/Educational Session Prevention Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since first relapse workshop. Recent insights that might provide a basis for development novel, practical clinical trials were emphasized, including utilization newer agents, optimization donor lymphocyte...
Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority patients ultimately die their disease. There no standard approach to treating alloHSCT. Withdrawal immune suppression donor lymphocyte infusions are commonly used all diseases; although these interventions remarkably effective relapsed chronic myelogenous leukemia, they limited efficacy in other hematologic...
Abstract Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). However, many individuals are unable to collect optimal CD34 + and progenitor (HSPC) numbers with granulocyte colony-stimulating factor (G-CSF) mobilization. Motixafortide is a novel cyclic-peptide CXCR4 inhibitor extended vivo activity. The GENESIS trial was prospective, phase 3, double-blind, placebo-controlled, multicenter study the objective of assessing superiority...
Background. Most patients infected with Epstein-Barr virus (EBV) are asymptomatic, have nonspecific symptoms, or self-limiting infectious mononucleosis. EBV, however, may result in severe primary disease cancer. Methods. We report EBV diseases associated GATA2 deficiency at one institution and describe the hematology, virology, cytokine findings. Results. Seven developed disease. Three presented mononucleosis requiring hospitalization, 1 had chronic active (B-cell type), EBV-associated...
The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions GVHD and improved outcomes allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year first multicenter prospective clinical trial PTCy setting mismatched unrelated donor (MMUD) bone marrow HCT. study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity (RIC;...
Solid organ transplant recipients (SOTR) receiving post-transplant immunosuppression show increased COVID-19-related mortality. It is unclear whether an additional dose of COVID-19 vaccines can overcome the reduced immune responsiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.We analysed humoral responses SARS-CoV-2 and its variants in 53 SOTR vaccination.Following initial vaccination series, 60.3% showed no measurable neutralisation only 18.9%...
Abstract Background Aggressive B cell lymphoma with secondary central nervous system (CNS) involvement (SCNSL) carries a dismal prognosis. Chimeric antigen receptor (CAR) T cells (CAR-T) targeting CD19 have revolutionized the treatment for lymphomas; however, only single cases CNS manifestations successfully treated CAR-T been reported. Methods We prospectively enrolled 4 patients SCNSL into our study to assess clinical responses and monitor immunity. Results Two of four SNCSL responded...
Summary In the relapsed/refractory setting for treatment of large B‐cell lymphoma (LBCL), chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as an effective modality. Patients often have aggressive disease that requires prompt in form bridging (BT) stabilisation while CAR‐T cells are manufactured. ( n = 75) undergoing infusion LBCL at our institution were identified. A total 52 (69·3%) received BT and 23 (30·7%) no (NBT). modalities included systemic (SBT) 28 patients, radiation...
In the National Cancer Institute's Second Workshop on Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, Scientific/Educational Session Biology discussed recent advances in understanding some host-, disease-, transplantation-related contributions to relapse, emphasizing concepts with potential therapeutic implications. hematopoietic stem cell transplantation (HSCT) represents tumor escape, from cytotoxic effects conditioning regimen immunologic...